Pharmaceutical

Amylyx considers scrapping ALS drug following Phase III flop

Amylyx’s stocks plummeted by more than 85% after announcing it is considering scrapping the drug due to the trial failure.

Mar 9, 2024 - 18:00
Amylyx considers scrapping ALS drug following Phase III flop
Amylyx’s stocks plummeted by more than 85% after announcing it is considering scrapping the drug due to the trial failure.
Read the original article

Tags:

Previous Article

AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine  

Next Article

Oligonucleotides: Overcoming sustainability challenges with manufacturing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves Celltrion’s subcutaneous Remicade biosimilar for IBD

FDA approves Celltrion’s subcutaneous Remicade biosimil...

Oct 23, 2023

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson agrees to acquire Ambrx Biopharma for...

Jan 9, 2024

CDC director overhauls leadership of center that oversaw response to Covid-19

CDC director overhauls leadership of center that oversa...

Aug 9, 2023